NCT06458374

ATTR Cardiac Amyloidosis in a Selected Population

Prevalence and Long Tem Follow Up of ATTR Cardiac Amyloidosis in a Selected Population of Patients Operated on Carpal Tunnel Syndrome

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 180 (estimated)
• Sponsor: Helse Møre og Romsdal HF · Other Government
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.

Detailed description

Biopsy proven ATTR (v/wt) amyloidosis inpatients operated with CTS will undergo standard guidelines recommended examinations as 99mTcDPD SPECT CT, echocardiography, ECG, Holter, genetic testing (v/wt), and lab testing, and CMRI as indicated. Exclusion of light chain disease will be done. All patients will be followed at least yearly as indicated by guidelines (ESC), and patients with development of cardiac amyloidosis will get standard treatment in accordance with guidelines and as approved by the Norwegian government. All patients will be followed for 10 years.

Conditions

• ATTR Amyloidosis Wild Type
• ATTR Gene Mutation
• Carpal Tunnel Syndrome
• Cardiac Amyloidosis

Timeline

• Start date: 2024-09-01
• Primary completion: 2034-02-28
• Completion: 2039-02-28
• First posted: 2024-06-13
• Last updated: 2024-10-16

Locations

1 site across 1 country: Norway